Insight Molecular Diagnostics Inc. has 2 Schedule 13D or 13G filings on record since 2026-02-12. 1 holder's latest filing reports 5% or more of common stock, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Broadwood Partners, L.P. | 39.7% | 12,834,977 | SCHEDULE 13D/A, 2026-04-27 | 2026-04-23 |
Purpose of Transaction (Item 4)
Broadwood Partners, L.P.
The Reporting Persons are filing this Schedule 13D/A to report a change in their respective beneficial ownership percentages. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may take such actions with respect to their investment in the Issuer as they deem appropriate. In that regard, the Reporting Persons have been and may continue to be in contact with members of the Issuer's management, board of directors (the "Board of Directors"), other significant shareholders and others regarding alternatives that the Issuer could employ to create significant additional shareholder value over time. The Reporting Persons further reserve the right to act in concert with any other shareholders of the Issuer, or other persons, for a common purpose should they determine to do so, and/or to recommend courses of action to shareholders, the Board of Directors and/or the management of the Issuer. Except as otherwise set forth herein, the Reporting Persons do not have any present plans or proposals which would relate to, or result in, the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D. However, subject to market conditions and in compliance with applicable securities laws, the Reporting Persons …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-04-27; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-12 | Broadwood Partners, L.P. | 37.4% | SCHEDULE 13D/A |
| 2026-04-27 | Broadwood Partners, L.P. | 39.7% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Insight Molecular Diagnostics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.